Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

PHASE2

Phase

SUSPENDED

Status

Enrollment

OTHER

Sponsor class

Stopped Per sponsor memo screening and enrollment of new patients for all ongoing Regeneron sponsored studies with vidutolimod are being paused until further notice

Conditions

Metastatic Prostate Adenocarcinoma
Stage IV Prostate Cancer AJCC v8

Interventions

DRUG: VLP-encapsulated TLR9 Agonist CMP-001,
BIOLOGICAL: Nivolumab

Sponsor

Emory University

Collaborators

[object Object]
[object Object]